Search the Newsreel

Will Home Depot (HD) Stock Rise or Fall After Q2 Earnings?

Home Depot Stock (HD) Could Move 4.3% on Q2 Earnings, Options Market Signals

CORT Looks 65.7% Overvalued on GF Value™

Corcept Therapeutics (CORT) has seen a significant stock gain of 228.94% year-to-date but is deemed 65.7% overvalued by GuruFocus' GF Value™ metric, trading at $114.47 against an intrinsic value of $69.10. Despite a strong GF Score™ of 85/100, reflecting robust growth and profitability, the …

B.C.'s Only Permitted Mill Signs a New Precious-Metals Partner

Nicola Mining Inc. has signed a Mining and Milling Profit Share Agreement with Red Eye Resources Ltd., a privately held precious metals explorer based in British Columbia. Under this agreement, Red Eye Resources can transport qualifying precious-metal material to Nicola's Merritt Mill for processing, …

Nicola Mining Enters into Mining and Milling Profit Share Agreement with Red Eye Resources

Nicola Mining Inc. announced a Mining and Milling Profit Share Agreement with Red Eye Resources Ltd., a privately held mineral exploration company. Under the agreement, Red Eye Resources will transport qualifying precious-metal mineralized material to Nicola's Merritt Mill for processing, with profits shared equally. …

Nicola Mining: Exclusive mill licence brings new profit-sharing arrangement

Nicola Mining has expanded its market position by entering a profit-sharing agreement with Red Eye Resources. This partnership will utilize Nicola's fully permitted Merritt Mill in British Columbia, the only facility authorized to process third-party gold and silver ore in the region. The collaboration …

Nicola Mining partners with Red Eye Resources to share profits from precious metal milling in BC.

Nicola Mining Inc. has entered a profit-sharing agreement with Red Eye Resources, allowing Red Eye to process mineralized material at Nicola's Merritt Mill in British Columbia. The partnership focuses on precious metals, with profits split equally, and aims to support smaller mining projects without …

EYPT Stock Slips As Insider Plans Share Sale

EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider …

Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com

This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.

Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com

Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in …

EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65

Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of …

Home Depot (HD) Stock Looks Fairly Valued After CEO Medical Leave

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Home Depot stock has delivered a 17.1% gain over the past five years, and current checks suggest it now trades close to what a …

How Olipop hit $500M in revenue and beat Pepsi's Poppi: Fmr CEO

Olipop Co-Founder and former CEO Ben Goodwin breaks down to Yahoo Finance Executive EditorBrian Sozzi the brand's massive $500 million growth, how they reclaimed the top spot from Poppi, and why health-conscious consumers ultimately don't trust Big Soda giants like Coke and Pepsi. Ben …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital

SK Hynix Shares Gain 3.9% with U.S. ADRs Trading at 48% Premium

Stifel Nicolaus Increases Home Depot (NYSE:HD) Price Target to $340.00

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics announced an End-of-Phase 2 meeting with the U.S. FDA on October 1, 2026, to align on the design of a pivotal Phase 3 trial for RAD101. This imaging agent diagnoses recurrent brain metastases and showed 93% concordance with MRI in its Phase …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to distinguish recurrent brain metastases from treatment …

EYPT Looks 4000.0% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but …

PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026

PROCEPT BioRobotics SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings …

PROCEPT sets a Sept. 15 New York date with healthcare investors

PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management team will participate in the Baird 2026 Global Healthcare Conference in New York City on September 15, 2026. They will present and host investor meetings at the conference. Following this announcement, the company's stock, PRCT, experienced …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

Weekly Recap: JDE Peet's deal and Aaron Alt named independent director

Keurig Dr Pepper (KDP) exceeded Q2 estimates with $7.31 billion in sales and $210 million net income, partly due to the JDE Peet's deal. The company also announced the appointment of Aaron Alt as an independent director and launched new co-branded Dr Pepper shakes …

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

Mobilicom Is Set for This Moment: Positioned to Capture Growing U.S. Market Demand Following New Federal Tariff Policy

Mobilicom is strategically positioned to benefit from new U.S. tariffs on foreign-made drones, leveraging its existing U.S. onshore production, FCC Trusted Drone status, and comprehensive U.S. defense compliance. The company's CEO, Oren Elkayam, stated that Mobilicom's long-term strategy and investments are now aligning to …

Option Volatility And Earnings Report For Aug 17-21

American flag on NY Stock Exchange by Chameleonseye via iStock It's all about retail earnings this week with Walmart (WMT), Home Depot (HD), Target (TGT) and Alibaba (BABA) all set to report. Before a company reports earnings, implied volatility is usually high because the …

Which Pressures Are Holding Back Smith & Nephew (LSE:SN.) And ConvaTec (LSE:CTEC) Right Now?

GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP has acquired a new stake in Sarepta Therapeutics (NASDAQ:SRPT), purchasing 103,618 shares valued at approximately $1.86 million, representing 0.10% of the company. Other institutional investors have also adjusted their holdings in SRPT, with institutional ownership collectively standing at 86.68%. Despite …

Free cash flow per share of Einride AB – NASDAQ:ENRDW

The article displays financial information for Einride AB (NASDAQ: ENRDW), specifically focusing on its free cash flow per share. It presents a table layout for financial data, allowing users to view period values and changes, but the values themselves are not provided in this …

What’s Going On With Independent Bank (INDB)?

Why the Copper Squeeze May Reward This Mining Stock More Than Nvidia

Reddit S&P 500 inclusion sends RDDT stock higher. Photo by BeInCrypto As an AI-fueled supply squeeze grips copper, Freeport-McMoRan (FCX) is emerging as the standout among copper stocks. The largest US copper miner trades near $66.50 after a sharp year-to-date run, its chart is …

6,665 Shares in Republic Services, Inc. $RSG Bought by Trivium Point Advisory LLC

Trivium Point Advisory LLC recently purchased 6,665 shares of Republic Services, Inc. (NYSE:RSG) valued at approximately $1.42 million, marking a new position for the firm. Other institutional investors have also adjusted their holdings in the waste management company, with Norges Bank acquiring a significant …

Can NYSE Composite Home Depot (NYSE:HD) Earnings Clarify Pro Demand?

Home Depot Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Walmart, Target, Home Depot Q2 Preview: Reading The US Consumer As Inflation Plateaus

Wall Street analysts are anticipating year-on-year growth in earnings and revenue for Home Depot, Target, and Walmart in their Q2 reports, despite varying same-store sales growth estimates. The reports come as US core inflation shows signs of plateauing, potentially impacting consumer spending trends. Each …